Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma 25Small Cell Lung Carcinoma 23Leukemia 18Lymphoma, Large B-Cell, Diffuse 17Lung Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 14Lymphoma, Extranodal NK-T-Cell 11Hodgkin Disease 10Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Neuroblastoma 7Lymphoma, Mantle-Cell 7Burkitt Lymphoma 7Recurrence 6Lymphoma, T-Cell, Peripheral 6Central Nervous System Neoplasms 6Retinoblastoma 5Lymphoma, Large-Cell, Immunoblastic 5Lymphohistiocytosis, Hemophagocytic 5Breast Neoplasms 5Testicular Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Teratoma 3

Interventions

Docetaxel 2Sunitinib 1Prednisone 1PE regimen 1Injections 1Etoposide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hormone Refractory Prostate Cancer × Etoposide × Clear all
NCT02208583 2014-08-05

Molecular Phenotype Changes and Personalized Treatment for CRPC

Tianjin Medical University Cancer Institute and Hospital

Phase NA Unknown
150 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡